Metastasin S100A4 is increased in proportion to radiographic damage in patients with RA

Rheumatology

Volumn 51, Issue 5, 2012, Pages 932-940

  Erlandsson, Malin C ^a   Forslind, Kristina ^b   Andersson, Sofia E M ^a   Lund, Annelie ^a   Bokarewa, Maria I ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Biological treatment; Radiographic damage; Rheumatoid arthritis; S100A4; Survivin

Indexed keywords

C REACTIVE PROTEIN; CALVASCULIN; CARBOXY TERMINAL TELOPEPTIDE; CHLORAMBUCIL; DRUG ANTIBODY; FLT3 LIGAND; INFLIXIMAB; INTERLEUKIN 6; METHOTREXATE; SOMATOMEDIN C; STROMELYSIN; SURVIVIN;

ADULT; AGED; ARTICLE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG TREATMENT FAILURE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; INFLAMMATION; JOINT RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BONE AND BONES; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; FOOT; HAND; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MEMBRANE PROTEINS; METHOTREXATE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; S100 PROTEINS;

EID: 84860255148     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker362     Document Type: Article

References (49)

1. Askling J, Fored CM, Baecklund E et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1414-20.
2. Martin DN, Mikhail IS, Landgren O. Autoimmunity and hematologic malignancies: associations and mechanisms. Leuk Lymphoma 2009;50:541-50.
3. Smedby KE, Hjalgrim H, Askling J et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 2006;98:51-60.
4. Baecklund E, Ekbom A, Sparen P et al. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998;317:180-1.
5. Gridley G, Klippel JH, Hoover RN, Fraumeni JF Jr. Incidence of cancer among men with the Felty syndrome. Ann Intern Med 1994;120:35-9.
6. Franklin JP, Symmons DP, Silman AJ. Risk of lymphoma in patients with RA treated with anti-TNFalpha agents. Ann Rheum Dis 2005;64:657-8.
7. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004;50: 1740-51.
8. Geborek P, Bladstrom A, Turesson C et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005;64:699-703.
9. Depper JM, Zvaifler NJ. Epstein-Barr virus. Its relationship to the pathogenesis of rheumatoid arthritis. Arthritis Rheum 1981;24:755-61.
10. Balandraud N, Meynard JB, Auger I et al. Epstein-Barr virus load in the peripheral blood of patients with rheumatoid arthritis: accurate quantification using real-time polymerase chain reaction. Arthritis Rheum 2003;48:1223-8.
11. Magnusson M, Brisslert M, Zendjanchi K et al. Epstein-Barr virus in bone marrow of rheumatoid arthritis patients predicts response to rituximab treatment. Rheumatology 2010;49:1911-9.
12. Stranges PB, Watson J, Cooper CJ et al. Elimination of antigen-presenting cells and autoreactive T cells by Fas contributes to prevention of autoimmunity. Immunity 2007; 26:629-41.
13. Greten FR, Eckmann L, Greten TF et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285-96.
14. Pikarsky E, Porat RM, Stein I et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004;431:461-6.
15. Allavena P, Garlanda C, Borrello MG et al. Pathways connecting inflammation and cancer. Curr Opin Genet Dev 2008;18:3-10.
16. Mantovani A, Sozzani S, Locati M et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23:549-55.
17. Khan OM, Ibrahim MX, Jonsson IM et al. Geranylgeranyltransferase type I (GGTase-I) deficiency hyperactivates macrophages and induces erosive arthritis in mice. J Clin Invest 2011;121:628-39.
18. Pap T, Nawrath M, Heinrich J et al. Cooperation of Ras- and c-Myc-dependent pathways in regulating the growth and invasiveness of synovial fibroblasts in rheumatoid arthritis. Arthritis Rheum 2004;50: 2794-802.
19. Szekanecz E, Andras C, Sandor Z et al. Malignancies and soluble tumor antigens in rheumatic diseases. Autoimmun Rev 2006;6:42-7.
20. Firestein GS, Nguyen K, Aupperle KR et al. Apoptosis in rheumatoid arthritis: p53 overexpression in rheumatoid arthritis synovium. Am J Pathol 1996;149:2143-51.
21. Seemayer CA, Kuchen S, Neidhart M et al. p53 in rheumatoid arthritis synovial fibroblasts at sites of invasion. Ann Rheum Dis 2003;62:1139-44.
22. Bokarewa M, Lindblad S, Bokarew D, Tarkowski A. Balance between survivin, a key member of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid arthritis. Arthritis Res Ther 2005;7: R349-58.
23. Svensson B, Hafstrom I, Forslind K et al. Increased expression of proto-oncogene survivin predicts joint destruction and persistent disease activity in early rheumatoid arthritis. Ann Med 2010;42:45-54.
24. Klingelhofer J, Senolt L, Baslund B et al. Up-regulation of metastasis-promoting S100A4 (Mts-1) in rheumatoid arthritis: putative involvement in the pathogenesis of rheumatoid arthritis. Arthritis Rheum 2007;56:779-89.
25. Garrett SC, Varney KM, Weber DJ, Bresnick AR. S100A4, a mediator of metastasis. J Biol Chem 2006;281: 677-80.
26. Santamaria-Kisiel L, Rintala-Dempsey AC, Shaw GS. Calcium-dependent and -independent interactions of the S100 protein family. Biochem J 2006;396:201-14.
27. Senolt L, Grigorian M, Lukanidin E et al. S100A4 is expressed at site of invasion in rheumatoid arthritis synovium and modulates production of matrix metalloproteinases. Ann Rheum Dis 2006;65:1645-8.
28. Oslejsková L, Grigorian M, Hulejová H et al. Metastasis-inducing S100A4 protein is associated with the disease activity of rheumatoid arthritis. Rheumatology 2009;48:1590-4.
29. Yammani RR, Long D, Loeser RF. Interleukin-7 stimulates secretion of S100A4 by activating the JAK/STAT signaling pathway in human articular chondrocytes. Arthritis Rheum 2009;60:792-800.
30. Mazzetti I, Magagnoli G, Paoletti S et al. A role for chemokines in the induction of chondrocyte phenotype modulation. Arthritis Rheum 2004;50:112-22.
31. Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum 2006;54:2784-92.
32. van Gestel AM, Prevoo ML, van't Hof MA et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
33. van der Heijde DM, van Leeuwen MA, van Riel PL et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992;35:26-34.
34. Helle M, Boeije L, Aarden LA. Functional discrimination between interleukin 6 and interleukin 1. Eur J Immunol 1988;18:1535-40.
35. Curtis JR, Jain A, Askling J et al. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum 2010;40:2-14. e1.
36. Soderlin MK, Geborek P. Changing pattern in the prescription of biological treatment in rheumatoid arthritis. A 7-year follow-up of 1839 patients in southern Sweden. Ann Rheum Dis 2008;67:37-42.
37. Garnero P, Landewe R, Boers M et al. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum 2002;46:2847-56.
38. Lindqvist E, Eberhardt K, Bendtzen K et al. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005;64:196-201.
39. Young-Min S, Cawston T, Marshall N et al. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis Rheum 2007;56:3236-47.
40. Syversen SW, Goll GL, van der Heijde D et al. Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression. J Rheumatol 2009;36: 266-72.
41. Smolen JS, Han C, van der Heijde DM et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 2009;68:823-7.
42. Grigor C, Capell H, Stirling A et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9.
43. van Leeuwen MA, van der Heijde DM, van Rijswijk MH et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J Rheumatol 1994;21:425-9.
44. Hyrich KL, Watson KD, Lunt M, Symmons DP. Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. Rheumatology 2011;50:117-23.
45. Deane KD, O'Donnell CI, Hueber W et al. The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner. Arthritis Rheum 2010;62: 3161-72.
46. Osterreicher CH, Penz-Osterreicher M, Grivennikov SI et al. Fibroblast-specific protein 1 identifies an inflammatory subpopulation of macrophages in the liver. Proc Natl Acad Sci USA 2011;108:308-13.
47. Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology 2007;46:1828-34.
48. Finckh A, Ciurea A, Brulhart L et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis 2010;69:387-93.
49. Radstake TR, Svenson M, Eijsbouts AM et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009;68: 1739-45.